Shares in Australian-listed wastewater treatment specialist Emefcy rose to an all-time high of A$1.12 on Monday after the company announced a breakthrough partnership which will accelerate sales of its membrane aerated biofilm reactor technology in China.
The deal will see local consulting engineering firm Beijing Sinorichen Environmental Protection deploy Emefcy’s technology in wastewater treatment installations serving rural communities throughout Northern China. The first of these will be an energy-efficient 20,000 litres per day demonstration system in Miyun district which the company hopes will provide the necessary performance data for it to obtain provincial certification by Q3 2017 in the key province of Beijing, where it believes the addressable market is worth A$75 million (US$57 million).
Emefcy has ridden a wave of optimism on the deployment potential of its MABR technology, and plans to begin manufacturing modules in China next year. Its shares have risen 460% since the December 2015 IPO.